12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Company News  |  Deals

Actavis Inc., Amgen deal

Actavis and Amgen disclosed the four cancer drugs for which they are developing biosimilars under a 2011 deal. The drugs include Herceptin trastuzumab, Avastin bevacizumab, Rituxan rituximab and Erbitux cetuximab. Actavis, which changed its name from

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >